ARK Genomic Revolution ETF
ARKG
238 hedge funds and large institutions have $699M invested in ARK Genomic Revolution ETF in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 102 reducing their positions, and 41 closing their positions.
31% more capital invested
Capital invested by funds: $535M → $699M (+$164M)
20% more call options, than puts
Call options by funds: $87.7M | Put options by funds: $73.1M
13.19% more ownership
Funds ownership: 41.64% → 54.83% (+13%)
9% less funds holding
Funds holding: 261 → 238 (-23)
46% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 41
64% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 102
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$36.8M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$26M |
| 3 |
Goldman Sachs
New York
|
+$23M |
| 4 |
Citigroup
New York
|
+$21.6M |
| 5 |
JP Morgan Chase
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$10.9M |
| 2 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
-$8.29M |
| 3 |
GS
GTS Securities
New York
|
-$5.94M |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$3.21M |
| 5 |
Morgan Stanley
New York
|
-$3.16M |
ARKG Hedge Fund Activity: Q3 2024 in Review
238 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q3 2024, worth a combined $699M — up 31% from $535M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of ARKG and 22 opened new positions — a net loss of 19 holders — while 102 trimmed existing stakes and 37 added.
The largest buyer was Bank of America, adding an estimated $36.8M. The largest seller was UBS Group, cutting an estimated $10.9M.
- 238 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q3 2024, down from 261 in Q2 2024.
- Funds reported $699M of ARK Genomic Revolution ETF stock for Q3 2024, up 31% quarter-over-quarter.
- 22 funds opened new ARK Genomic Revolution ETF positions in Q3 2024 and 41 closed out, a net change of -19 holders.
- The largest ARK Genomic Revolution ETF buyer in Q3 2024 was Bank of America, an estimated $36.8M added.
- The largest ARK Genomic Revolution ETF seller in Q3 2024 was UBS Group, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2024.